Recent Updates
Recently added Catalysts
NRIX Positive Sentiment

Test

Key Takeaway: Nurix is pioneering targeted protein degradation to combat diseases, emphasizing the development of Degrader Antibody Conjugates (DACs) for improved treatment precision. Their DEL-AI drug discovery engine aims to advance a diverse pipeline in oncology, immunology, and neurology. The company is committed to delivering safer and more effective patient care.
Price reaction · baseline $14.64 (2026-06-05 close) · 5 other NRIX headline(s) in the window, move may be shared
day 0 close
+6.8%
day 1
+6.8%
day 3 · peak
+16%

Market Sentiment Analysis

POSITIVE FACTORS

  • Innovative approach using targeted protein degradation.
  • Potential for enhanced precision and improved safety in treatments.
  • Focus on a multi-modal pipeline targeting various diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma

Full Press Release Details

Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease.
More About Nurix
Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease.
More About Nurix
Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease.
More About Nurix
OUR SCIENCE

Targeted protein degradation

• Degraders
• Degrader Antibody Conjugates (DACs)
• The DEL-AI Advantage
• Our Pipeline
Our degraders are designed to eliminate disease-causing proteins by harnessing the cell’s natural protein degradation machinery.
More On Degraders
Our DACs combine the cell specificity of antibodies with the potency, selectivity, and catalytic activity of degraders, delivering innovative medicines with the potential for enhanced precision and improved safety.
More On DACs
Our innovative and prolific DEL-AI drug discovery engine is powering the protein degradation revolution.
Explore Our Technology
We are translating the science of degradation into clinical progress, advancing a multi-modal pipeline that targets a broad range of diseases in oncology, immunology, and neurology.
See Our Pipeline
OUR MISSION

Establishing degrader-based medicines at the forefront of patient care

We are steadfast in our pursuit to provide patients with safer, deeper, more durable responses for sustained disease control.
See Our Clinical Trials
OUR CULTURE

Surpass what is possible

We believe in the transformative power of targeted protein degradation to unlock a new universe of treatment options for patients. Join us in writing medicine’s next chapter.
Search Career Opportunities
OUR FOCUS

The latest at Nurix

See All News

Frequently Asked Questions

What is Nurix's main focus?

Nurix focuses on targeted protein degradation to develop innovative medicines.

What are Degrader Antibody Conjugates?

DACs combine antibodies' specificity with the potency of degraders for precise treatments.

What diseases does Nurix target?

Nurix targets a broad range of diseases in oncology, immunology, and neurology.

How does Nurix ensure patient safety?

Nurix aims to provide safer, deeper, and more durable responses for sustained disease control.

Last updated: Jun 6, 2026